| |
| |
|
| Insider
Information: |
Henney Christopher S |
| Relationship: |
Director |
| City: |
Seattle |
| State: |
WA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
7 |
|
| Direct
Shares |
1,304,748 |
|
|
Indirect Shares
|
100,000 |
|
|
| Direct
Value |
$15,372 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
1,404,748 |
|
|
| Total
Value |
$15,372 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
2
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-2.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -56.7%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Dendreon Corp |
DNDN |
Chaiman of the Board, ... |
2004-02-17 |
1,062,904 |
2003-07-28 |
0 |
Premium* |
|
|
Techne Corp |
TECH |
Director |
2004-09-17 |
0 |
2003-08-20 |
0 |
Premium* |
|
|
Sgx Pharmaceuticals, Inc. |
SGXP |
Director |
2008-08-20 |
0 |
|
0 |
Premium* |
|
|
Cascadian Therapeutics, Inc |
CASC |
Director |
2018-03-09 |
0 |
2007-12-10 |
0 |
Premium* |
|
|
Anthera Pharmaceuticals Inc |
ANTH |
Director |
2012-06-29 |
202,429 |
2012-06-29 |
100,000 |
Premium* |
|
|
Prothena Corp Plc |
PRTA |
Director |
2021-07-14 |
0 |
2015-08-07 |
0 |
Premium* |
|
|
Cyclacel Pharmaceuticals Inc |
CYCC |
Director |
2023-06-30 |
39,415 |
2021-06-15 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
78 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| SGXP |
Sgx Pharmaceuticals, Inc. |
officerTitle |
– • – |
2006-01-31 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
77,587 |
|
- |
|
| ANTH |
Anthera Pharmaceuticals I... |
Director |
– • – |
2010-02-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
14,602 |
|
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2012-05-03 |
4 |
D |
$4.15 |
$1,025 |
D/D |
(247) |
106,288 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2017-06-12 |
4 |
D |
$3.34 |
$1,794 |
D/D |
(537) |
51,611 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2017-09-24 |
4 |
D |
$3.94 |
$2,340 |
D/D |
(594) |
60,185 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2011-12-31 |
4 |
D |
$7.58 |
$4,525 |
D/D |
(597) |
105,546 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2016-06-06 |
5 |
D |
$7.38 |
$5,026 |
D/D |
(681) |
50,000 |
0 |
- |
|
| PRTA |
Prothena Corp Plc |
Director |
– • – |
2017-09-28 |
4 |
OE |
$6.65 |
$5,985 |
D/D |
900 |
900 |
0 |
- |
|
| PRTA |
Prothena Corp Plc |
Director |
– • – |
2017-09-28 |
4 |
AS |
$70.00 |
$63,000 |
D/D |
(900) |
0 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2012-05-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
989 |
106,535 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2013-06-09 |
4 |
D |
$1.86 |
$2,111 |
D/D |
(1,135) |
111,306 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2011-12-04 |
4 |
D |
$6.86 |
$10,606 |
D/D |
(1,546) |
103,755 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2012-06-03 |
4 |
D |
$3.51 |
$7,094 |
D/D |
(2,021) |
104,267 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2014-06-07 |
4 |
D |
$3.06 |
$6,255 |
D/D |
(2,044) |
123,776 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2011-06-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,076 |
49,051 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2017-06-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,148 |
52,148 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2017-06-24 |
4 |
D |
$3.78 |
$8,562 |
D/D |
(2,265) |
58,404 |
0 |
- |
|
| CYCC |
Cyclacel Pharmaceuticals ... |
Director |
– • – |
2021-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
2,374 |
2,374 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2017-09-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,375 |
60,779 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2011-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,388 |
106,143 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2016-06-06 |
5 |
OE |
$0.00 |
$0 |
D/D |
2,723 |
50,861 |
0 |
- |
|
| TECH |
Techne Corp |
Director |
– • – |
2004-09-17 |
4 |
S |
$40.76 |
$122,280 |
D/D |
(3,000) |
0 |
|
- |
|
| TECH |
Techne Corp |
Director |
– • – |
2004-09-17 |
4 |
OE |
$29.10 |
$87,300 |
D/D |
3,000 |
3,000 |
|
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2010-12-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,166 |
42,437 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2014-06-13 |
4 |
D |
$3.88 |
$15,563 |
D/D |
(4,011) |
135,807 |
0 |
- |
|
78 Records found
|
|
Page 1 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
